Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …

The change in Gibbs energy when an ion or molecule moves from a vacuum to a solvent is
known as solvation energy and solvation is the process of attracting and associating …

Heart failure is a significant public health concern characterized by notable rates of morbidity
and mortality. Despite the presence of guideline-directed medical therapy (GDMT), its …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Background In real-world clinical practice, the initiation and up-titration of sacubitril/valsartan
remain challenging due to symptomatic hypotension in patients with acute myocardial …

Aims Angiotensin receptor neprilysin inhibitor (ARNI) therapy is a cornerstone in the
treatment of heart failure with reduced ejection fraction (HFrEF), with significant improvement …

Despite previous studies showing that patients with low systolic blood pressure (sBP) in
heart failure with reduced ejection fraction (HFrEF) has a poor prognosis, it has few …

BACKGROUND It is not clear whether sacubitril/valsartan is beneficial for patients with heart
failure (HF) with reduced ejection fraction (HFrEF) and low systolic blood pressure (SBP) …

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …

Angiotensin receptor/neprilysin inhibitors (ARNI) have become a pillar of heart failure (HF)
management. Clinicians gain practical insight into the use of sacubitril/valsartan in patients …